KRAS and familial pancreatic carcinoma: Although the PE system has advantages in correcting KRAS mutations, the correction efficiencies of two pancreatic cancer cell lines were much lower than those of HEK293T/17 cell lines and HCT116 colon cancer cells as previously described29.